Compile Data Set for Download or QSAR
Report error Found 2914 with Last Name = 'kattar' and Initial = 's'
TargetInterleukin-1 receptor-associated kinase 4(Rat)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50242696(CHEMBL4083650 | US9932350, 2-5)
Affinity DataEC50:  1.70E+3nMAssay Description:Inhibition of IRAK4 in Lewis rat whole blood assessed as reduction in R848-stimulated TNF alpha production after 4 hrsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2019
Entry Details Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Rat)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50242697(CHEMBL4070214 | US9932350, 2-7)
Affinity DataEC50:  2.30E+3nMAssay Description:Inhibition of IRAK4 in Lewis rat whole blood assessed as reduction in R848-stimulated TNF alpha production after 4 hrsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2019
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM50114800(CHEMBL3609749)
Affinity DataEC50:  1.30E+4nMAssay Description:Inhibition of human ERG expressed in CHO cells by patch clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/24/2016
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM50114805(CHEMBL3608384)
Affinity DataEC50:  9.00E+3nMAssay Description:Inhibition of human ERG expressed in CHO cells by patch clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/24/2016
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM50114806(CHEMBL3609752)
Affinity DataEC50:  2.20E+3nMAssay Description:Inhibition of human ERG expressed in CHO cells by patch clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/24/2016
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM50114807(CHEMBL3608385)
Affinity DataEC50:  1.30E+3nMAssay Description:Inhibition of human ERG expressed in CHO cells by patch clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/24/2016
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM50114810(CHEMBL3609754)
Affinity DataEC50:  9.00E+3nMAssay Description:Inhibition of human ERG expressed in CHO cells by patch clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/24/2016
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM50114837(CHEMBL3609755)
Affinity DataEC50:  7.50E+3nMAssay Description:Inhibition of human ERG expressed in CHO cells by patch clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/24/2016
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Research Laboratories

Curated by ChEMBL
LigandPNGBDBM50114845(CHEMBL3609759)
Affinity DataEC50:  1.50E+4nMAssay Description:Inhibition of human ERG expressed in CHO cells by patch clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/24/2016
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620868(US20230303540, Example Ex-6.34 | US20230303540, Ex...)
Affinity DataIC50: 0.0800nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620916((3S,4S) or (3R,4R) 4-(4-(6- chloro-2-((5-(difluoro...)
Affinity DataIC50: 0.0800nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620922((3R,4R)-4-(4-(6-chloro-2-((1- cyclopropyl-5-(diflu...)
Affinity DataIC50: 0.0800nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50584324(CHEMBL5088471)
Affinity DataIC50: 0.0800nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50630435(CHEMBL5407732)
Affinity DataIC50: 0.0800nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) using LRRKtide peptide as substrate assess...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2024
Entry Details
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50630441(CHEMBL5405380)
Affinity DataIC50: 0.0800nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) using LRRKtide peptide as substrate assess...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2024
Entry Details
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50630442(CHEMBL5433289)
Affinity DataIC50: 0.0800nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) using LRRKtide peptide as substrate assess...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2024
Entry Details
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620971((3S,4S) or (3R, 4R)-4-((R) or (S)- 4-(6-chloro-2-(...)
Affinity DataIC50: 0.0880nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620720(US20230303540, Example Ex-3.1)
Affinity DataIC50: 0.0930nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620851(US20230303540, Example Ex-5.1)
Affinity DataIC50: 0.105nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620733(1-{6-chloro-2-[(1-cyclopropyl-5- methyl-1H-pyrazol...)
Affinity DataIC50: 0.106nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50630443(CHEMBL5422978)
Affinity DataIC50: 0.110nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) using LRRKtide peptide as substrate assess...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2024
Entry Details
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620974(US20230303540, Example Ex-13.2 | US20230303540, Ex...)
Affinity DataIC50: 0.116nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277322(US10072025, Example 1-3 | tert-butyl 4-ethyl-4-(3-...)
Affinity DataIC50: 0.120nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM189867(US9670196, 2.3 (R or S)-5-hydroxy-5-{5-[3- methyl-...)
Affinity DataIC50: 0.129nMpH: 7.5 T: 2°CAssay Description:A recombinant GST-hSYK fusion protein was used to measure potency of compounds to inhibit human Syk activity. The recombinant human GST-SYK (Carna Bi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620858((3S,4S) or (3R,4R) 4-(4-{2-[(5- chloro-1-cycloprop...)
Affinity DataIC50: 0.170nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620778((3R,4R) or (3S,4S) 4-(4-(6-chloro- 2-((5-chloro-1-...)
Affinity DataIC50: 0.178nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620854((3S,4S) or (3R,4R) 4-(4-(2-((1- cyclopropyl-5-meth...)
Affinity DataIC50: 0.180nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277377(US10072025, Example 3-11 | tert-butyl 4-ethyl-4-[3...)
Affinity DataIC50: 0.190nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620857((3S,4S) or (3R,4R) 4-(4-{2-[(1- cyclopropyl-5-meth...)
Affinity DataIC50: 0.197nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277320(US10072025, Example 1-1 | tert-butyl 4-(3-(4-(N,N-...)
Affinity DataIC50: 0.200nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620779((R or S) 6-chloro-N-(5-chloro-1-((S) or (R) 2,2-d...)
Affinity DataIC50: 0.200nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620875(US20230303540, Example Ex-6.10 | 1-(6-chloro-2-{[1...)
Affinity DataIC50: 0.200nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50630444(CHEMBL5396547)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) using LRRKtide peptide as substrate assess...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2024
Entry Details
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620868(US20230303540, Example Ex-6.34 | US20230303540, Ex...)
Affinity DataIC50: 0.212nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620734({8-[6-chloro-2-({1-[3-(methoxymethyl) bicyclo[1.1....)
Affinity DataIC50: 0.218nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620731(1-(6-chloro-2-{[1-(2-hydroxy-2- methylpropyl)-1H-p...)
Affinity DataIC50: 0.221nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620734({8-[6-chloro-2-({1-[3-(methoxymethyl) bicyclo[1.1....)
Affinity DataIC50: 0.227nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277366(US10072025, Example 2-44 | 4-((1-(1-(tert- butoxyc...)
Affinity DataIC50: 0.230nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277367(US10072025, Example 3-1 | tert-butyl-4-ethyl-4-(3-...)
Affinity DataIC50: 0.25nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277377(US10072025, Example 3-11 | tert-butyl 4-ethyl-4-[3...)
Affinity DataIC50: 0.25nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620977((3S,4S) or (3R, 4R)-4-(4-(2-((1- (bicyclo[1.1.1]pe...)
Affinity DataIC50: 0.267nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620893((3S,4S) or (3R,4R) 4-[4-(6- chloro-2-{[5-chloro-1-...)
Affinity DataIC50: 0.270nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620719((3S,4S or 3R,4R)-N-(1- (bicyclo[1.1.1]pentan-1-yl)...)
Affinity DataIC50: 0.279nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277352(US10072025, Example 2-30 | tert-butyl 4-ethyl-4-(3...)
Affinity DataIC50: 0.290nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277376(US10072025, Example 3-10 | tert-butyl 4-ethyl-4-(3...)
Affinity DataIC50: 0.290nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277336(US10072025, Example 2-14 | tert-butyl 4-ethyl-4-(3...)
Affinity DataIC50: 0.300nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277372(US10072025, Example 3-6 | tert-butyl 4-ethyl-4-[3-...)
Affinity DataIC50: 0.300nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50590228(CHEMBL5172416 | US20240308980, Ex-1.41)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser9...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50609728(CHEMBL5267350)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured afte...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50609742(CHEMBL5286106)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed
Displayed 1 to 50 (of 2914 total ) | Next | Last >>
Jump to: